BR112022001575A2 - Formulações de anticorpos anti-pvrig e usos dos mesmos - Google Patents
Formulações de anticorpos anti-pvrig e usos dos mesmosInfo
- Publication number
- BR112022001575A2 BR112022001575A2 BR112022001575A BR112022001575A BR112022001575A2 BR 112022001575 A2 BR112022001575 A2 BR 112022001575A2 BR 112022001575 A BR112022001575 A BR 112022001575A BR 112022001575 A BR112022001575 A BR 112022001575A BR 112022001575 A2 BR112022001575 A2 BR 112022001575A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody formulations
- pvrig antibody
- pvrig
- formulations
- liquid pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880021P | 2019-07-29 | 2019-07-29 | |
| US201962893051P | 2019-08-28 | 2019-08-28 | |
| US201962930206P | 2019-11-04 | 2019-11-04 | |
| US202062968660P | 2020-01-31 | 2020-01-31 | |
| US202062985702P | 2020-03-05 | 2020-03-05 | |
| US202063009367P | 2020-04-13 | 2020-04-13 | |
| PCT/US2020/043921 WO2021021837A2 (en) | 2019-07-29 | 2020-07-28 | Anti-pvrig antibodies formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001575A2 true BR112022001575A2 (pt) | 2022-04-19 |
Family
ID=72243187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001575A BR112022001575A2 (pt) | 2019-07-29 | 2020-07-28 | Formulações de anticorpos anti-pvrig e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220280643A1 (https=) |
| EP (1) | EP4003417A2 (https=) |
| JP (1) | JP2022542505A (https=) |
| KR (1) | KR20220041881A (https=) |
| CN (1) | CN114615993A (https=) |
| AU (1) | AU2020323926A1 (https=) |
| BR (1) | BR112022001575A2 (https=) |
| CA (1) | CA3149093A1 (https=) |
| IL (1) | IL290141A (https=) |
| MX (1) | MX2022001146A (https=) |
| WO (1) | WO2021021837A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL317989A (en) | 2016-08-17 | 2025-02-01 | Compugen Ltd | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| WO2022069940A1 (en) * | 2020-09-30 | 2022-04-07 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
| WO2022171080A1 (zh) * | 2021-02-09 | 2022-08-18 | 上海君实生物医药科技股份有限公司 | 抗cd112r抗体及其用途 |
| EP4403574A4 (en) | 2021-09-15 | 2025-10-29 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PD-1-Specific Protein and Its Pharmaceutical Use |
| EP4403573A4 (en) * | 2021-09-15 | 2024-12-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING BISPECIFIC ANTI-PVRIG/TIGIT ANTIBODY |
| WO2024027824A1 (zh) * | 2022-08-05 | 2024-02-08 | 上海君实生物医药科技股份有限公司 | 抗cd112r抗体药物组合物及其用途 |
| CN120112553A (zh) * | 2022-08-10 | 2025-06-06 | 广州百济神州生物制药有限公司 | 抗pvrig抗体和使用方法 |
| CN117957254A (zh) * | 2022-08-31 | 2024-04-30 | 石药集团巨石生物制药有限公司 | 抗pvrig抗体及其应用 |
| KR20250156744A (ko) | 2023-03-15 | 2025-11-03 | 상하이 맙젠 바이오텍 리미티드 | Pd-1/pvrig/tigit 결합 단백질을 함유하는 약학적 조성물 및 이의 의약적 용도 |
| WO2024245388A1 (zh) * | 2023-06-01 | 2024-12-05 | 信达生物制药(苏州)有限公司 | 抗pvrig抗体及其应用 |
| TW202502812A (zh) * | 2023-06-06 | 2025-01-16 | 大陸商上海藥明生物技術有限公司 | 抗pvrig抗體及其用途 |
| CN120005023B (zh) * | 2023-12-22 | 2025-12-26 | 华润生物医药有限公司 | 抗pvrig抗体及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9714A (en) | 1853-05-10 | Machine fob making hook-headed spikes | ||
| US289A (en) | 1837-07-19 | Cooking-stove | ||
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP3409289B1 (en) * | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| DK3653221T5 (da) * | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| US10550173B2 (en) * | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
| WO2017165736A1 (en) * | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
| IL317989A (en) * | 2016-08-17 | 2025-02-01 | Compugen Ltd | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof |
| CR20190291A (es) * | 2016-12-23 | 2019-11-05 | Serum Institute Of India Pvt Ltd | Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
| JP7348072B2 (ja) * | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
| JP2023500651A (ja) * | 2019-11-04 | 2023-01-10 | コンピュジェン リミテッド | 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法 |
| WO2022069940A1 (en) * | 2020-09-30 | 2022-04-07 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
| WO2022165275A2 (en) * | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
| WO2022165266A1 (en) * | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| US12462008B2 (en) | 2021-04-23 | 2025-11-04 | Beijing Boe Technology Development Co., Ltd. | Unlocking control method and device, electronic apparatus, and computer-readable storage medium |
| WO2023064958A1 (en) * | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
| US20240103010A1 (en) * | 2022-03-18 | 2024-03-28 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
| TW202515608A (zh) * | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
-
2020
- 2020-07-28 EP EP20761926.3A patent/EP4003417A2/en active Pending
- 2020-07-28 JP JP2022505499A patent/JP2022542505A/ja active Pending
- 2020-07-28 BR BR112022001575A patent/BR112022001575A2/pt unknown
- 2020-07-28 MX MX2022001146A patent/MX2022001146A/es unknown
- 2020-07-28 AU AU2020323926A patent/AU2020323926A1/en active Pending
- 2020-07-28 CN CN202080060763.9A patent/CN114615993A/zh active Pending
- 2020-07-28 KR KR1020227006619A patent/KR20220041881A/ko active Pending
- 2020-07-28 CA CA3149093A patent/CA3149093A1/en active Pending
- 2020-07-28 US US17/631,847 patent/US20220280643A1/en active Pending
- 2020-07-28 WO PCT/US2020/043921 patent/WO2021021837A2/en not_active Ceased
-
2022
- 2022-01-26 IL IL290141A patent/IL290141A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL290141A (en) | 2022-03-01 |
| WO2021021837A3 (en) | 2021-03-11 |
| AU2020323926A1 (en) | 2022-03-10 |
| KR20220041881A (ko) | 2022-04-01 |
| US20220280643A1 (en) | 2022-09-08 |
| MX2022001146A (es) | 2022-03-17 |
| EP4003417A2 (en) | 2022-06-01 |
| JP2022542505A (ja) | 2022-10-04 |
| CA3149093A1 (en) | 2021-02-04 |
| WO2021021837A2 (en) | 2021-02-04 |
| CN114615993A (zh) | 2022-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022001575A2 (pt) | Formulações de anticorpos anti-pvrig e usos dos mesmos | |
| EP3882275A4 (en) | ANTI-PD-1 AND ANTI-VEGFA BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | |
| BR112018075649A2 (pt) | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo | |
| CY1123783T1 (el) | Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| BR112018075653A2 (pt) | anticorpos anti-b7-h3 e conjugados anticorpo fármaco | |
| BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
| EP3505535A4 (en) | MONOCLONAL ANTI-PD-1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | |
| EP3511346A4 (en) | BIFUNCTIONAL ANTI-CTLA4 AND ANTI-PD-1 ANTIBODIES, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | |
| IL281778A (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
| EP3618871A4 (en) | FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES | |
| MX381232B (es) | Formulación de anticuerpos. | |
| MX2022014781A (es) | Formulaciones de anticuerpos anti-pdl1. | |
| EP3941946A4 (en) | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | |
| CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
| EP3849609A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMORS WITH ANTI-CD19 ANTIBODIES AND NATURAL KILLER CELLS | |
| PH12021550096A1 (en) | Compositions of fcrn antibodies and methods of use thereof | |
| MA40612A (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
| BR112021016056A2 (pt) | Anticorpos de claudina 6 e usos dos mesmos | |
| MX2022006784A (es) | Formulaciones de anticuerpos anti-pd-l1. | |
| CO2021010697A2 (es) | Formulación de anticuerpos terapéuticos | |
| IL262514A (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| PT3710485T (pt) | Conjugados de fármaco e anticorpo anti-sez6 e métodos de utilização | |
| MA55761A (fr) | Formulations et anticorps anti-cd38 |